NATCO Pharma (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
NATCO Pharma Limited |
|||
|
Price: ₹1,416.95 | ||
| 52 Week Low: ₹755.00 52 Week High: ₹1,639.00 |
|||
| Market Capital: 24,279.25 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: NATCO Pharma Share Price Target For 2024
- 1.1.1: NATCO Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: NATCO Pharma Share Price Target For 2025
- 1.2.1: NATCO Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: NATCO Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: NATCO Pharma Brief Company Overview
- 4: NATCO Pharma Financial Performance
- 4.0.1: Is NATCO Pharma A Good Buy For Long Term?
To predict the NATCO Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
NATCO Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of NATCO Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for NATCO Pharma shares in 2024, see the table below.
NATCO Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1476.85 (+4.22%) | Price Action: 13 Dec 2024 High |
| 2024 Target 2 | 1462.0 (+3.17%) | Price Action: 18 Dec 2024 High |
| 2024 Target 1 | 1446.5 (+2.08%) | Price Action: 05 Dec 2024 High |
| Current Price | 1416.95 | NATCO Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1415.29 (-0.12%) | Fibonacci Retracement Level 71.80% |
| Stop Loss 2 | 1396.05 (-1.48%) | Price Action: 04 Nov 2024 Low |
| Stop Loss 3 | 1382.0 (-2.47%) | Price Action: 25 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: NATCO Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹1413.37 serves as the nearest technical reference point.
Historical Returns: 3-month: -0.10% | 6-month: +21.80% | 1-year: +75.39%
NATCO Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of NATCO Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for NATCO Pharma shares in 2025, see the table below.
NATCO Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2081.14 (+46.87%) | Fibonacci Extension Level 150.00% |
| 2025 Target 2 | 2022.24 (+42.71%) | Price Action: Chart |
| 2025 Target 1 | 2002.22 (+41.30%) | Fibonacci Extension Level 64.90% |
| Current Price | 1416.95 | NATCO Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1288.02 (-9.10%) | Price Action: Aug 2024 Low |
| Stop Loss 2 | 1256.42 (-11.33%) | Technical Indicator: MA200 |
| Stop Loss 3 | 1233.8 (-12.93%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: NATCO Pharma is currently trading at 74.9% of its 52-week range (₹755 - ₹1639).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +75.39% | 3-year: +60.66% | 5-year: +148.79%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
NATCO Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,416.95 | ||
| 2024 | ₹1,468.73 | +3.65% | ₹1,490.76 |
| 2025 | ₹2,047.50 | +39.41% | ₹2,078.21 |
| 2026 | ₹2,316.95 | +13.16% | ₹2,351.70 |
| 2027 | ₹2,592.43 | +11.89% | ₹2,631.32 |
| 2028 | ₹3,153.26 | +21.63% | ₹3,205.21 |
| 2029 | ₹3,615.08 | +14.65% | ₹3,784.07 |
| 2030 | ₹4,362.92 | +20.69% | ₹4,428.36 |
| 2031 | ₹4,453.78 | +2.08% | ₹4,520.59 |
| 2032 | ₹4,610.99 | +3.53% | ₹4,941.77 |
| 2033 | ₹5,277.69 | +14.46% | ₹5,520.63 |
| 2034 | ₹5,761.43 | +9.17% | ₹6,099.48 |
| 2035 | ₹6,678.33 | +15.91% | ₹6,778.50 |
| 2036 | ₹6,590.61 | -1.31% | ₹6,689.47 |
| 2037 | ₹6,629.56 | +0.59% | ₹7,257.19 |
| 2038 | ₹7,402.11 | +11.65% | ₹7,836.04 |
| 2039 | ₹7,944.78 | +7.33% | ₹8,414.90 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
NATCO Pharma Brief Company Overview
NATCO Pharma Limited: A Comprehensive Overview NATCO Pharma Limited, established in 1981, is a renowned pharmaceutical company headquartered in Hyderabad, India. The company has made a significant mark in the industry with its diverse product portfolio and global presence. ...
NATCO Pharma specializes in developing, manufacturing, and marketing finished dosage formulations and active pharmaceutical ingredients (APIs). Their product offerings span various therapeutic areas, including oncology, central nervous system, pain management, gastroenterology, cardiology, and diabetology. The company also caters to the agricultural sector with its agrochemicals and biological pest management solutions, providing comprehensive crop protection across a range of crops. NATCO Pharma's commitment to quality and innovation has earned them a reputation for excellence in the healthcare industry. They market their products in approximately 50 countries, demonstrating their strong global presence.NATCO Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 24,279.25 Crore | Market valuation of NATCO Pharma's shares. |
| Revenue (TTM) | 4,563.8 Crore | Total revenue generated by NATCO Pharma over the past twelve months. |
| Net Income (TTM) | +19,448,000,512.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +55.32% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +42.61% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+32.90% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+83.60% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
2.91 | Company's total debt divided by total shareholder equity. |
| Total Debt | 208.4 Crore | Sum of NATCO Pharma's current & long-term financial obligations. |
| Total Cash | 2,463.39 Crore | Total amount of liquid funds available to NATCO Pharma. |
| Beta | 0.51 | Beta is less than 1 indicating that the NATCO Pharma's price is less volatile than the market. |
Is NATCO Pharma A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
